Skip to main content

Profile: Jason Eriksen

Jason Eriksen
Jason Eriksen, Ph.D., PMP
Associate Professor of Pharmacology
Affiliate Member, UH Center for Nuclear Receptors

Department of Pharmacological and Pharmaceutical Sciences
Physical Address: Science and Research Building 2
3455 Cullen Blvd., Room 557A, Houston, TX 77204-5037
Mailing Address: Health and Biomedical Sciences Building 2, 4849 Calhoun Road, Room 3044, Houston, TX 77204-5037

713-743-1226
713-743-1229 (fax)
jeriksen@central.uh.edu

Education

B.S., Biology and English, Wake Forest University, Winston-Salem, NC
Ph.D., Neuroscience, Loyola University Chicago, Chicago, IL
Postdoctoral fellow, The Mayo Clinic, Jacksonville, FL

Professional Certifications

Project Management Professional, Project Management Institute (License 2101521)

Research Interests

Many neurodegenerative diseases, including Huntington's, Parkinson's, and Alzheimer's diseases, in human patients are both poorly understood and untreatable. In order to develop a deeper understanding of these disorders, a unifying theme in our lab is the study of mechanisms by which protein misfolding in the central nervous system leads to severe brain degeneration.
Our research suggests that the manipulation of protein quality control systems, including the ubiquitin-proteasome system, the autophagic pathway, and heat-shock proteins may all exert dramatic effects on the development of pathology in these diseases. We use a variety of approaches, ranging from simple biochemical assays to complex transgenic organisms, in order to better understand the specific molecular and biochemical pathways that are involved in these diseases.

Patents

Universal Antigen Retrieval Compounds and Methods of Use. UHID2014-001. Eriksen J.L., Vollert, C.V, Gregory, S., Moree, W, Bark S., USPTO Serial No.: 14/530,142. Nonprovisonal patent application.

Žiburkus, J; Feng, G.; Eriksen, J.L.; Methods of Treating Neurological Diseases. University of Houston. USPTO 20150051166 A1.

Annapragada, A.; Eriksen J. L.; Tanifum, E.; Dasgupta, I.; Cook, S., inventors; Lipid Based Nanoparticles. United States Application 20120258044. October 11, 2012.

Hutton, M.L.; Baker, M. C.; Gass, J. M.; Rademakers, R.; Eriksen, J. L.; Pickering-Brown, S.M.; Mackenzie, I.R.A; Feldman, H.; Kumar-Singh, S.; Van Broeckhoven, C.; Cruts, M.; Cannon, A.D.; Detecting and Treating Dementia. US 8486635 B2, Jul 16, 2013.

Eriksen J. L.; Dickson, D. W.; Baker, M. W.; Rademakers, R.; Robinson, T., inventors; Methods and Materials for Detecting and Treating Dementia. United States Patent 8,486,635. Issued 07/16/2013.

Selective Inhibition of ABeta42 by NSAID and NSAID Analogs. Mayo Medical Ventures and Myriad Pharmaceuticals, Inc. October 2, 2003. Licensed Invention Certificate.

Selective Inhibition of ABeta42 by NSAID and NSAID Analogs. Chiesi Farmaceutici S.p.A. October 8, 2001. Sponsored Research Funding.

Awards & Honors

  • 2007-2008 Smith Foundation Fellowship
  • 2002-2004 John Douglas French Alzheimer’s Foundation Fellowship
  • 2002 8th International Conference on Alzheimer's Disease and Related Disorders Travel Fellowship
  • 1998-2000 NRSA Predoctoral Fellowship (NIAAA, National Institutes of Health)
  • 1998-2000 Loyola University Dissertation Fellowship, Loyola University of Chicago
  • 1994-1998 Graduate Student Science Fellowship, Loyola University of Chicago
  • 1992 Hughes Undergraduate Grant in Biology

Editorships

  • Review Editor, Neural Regeneration Research (2010-Present)
  • Review Editor, Frontiers in Neuroscience (2010-Present)
  • Associate Editor, Scientific Reports (2015-Present)

Invited Reviewer

  • Acta Neuropathologica
  • Journal of Alzheimer’s Disease
  • Journal of Psychopharmacology
  • Molecular Neurobiology
  • Neuropsychopharmacology
  • Neuroscience Letters
  • PLoS One
  • Scientific Reports
  • Translational Neuroscience

Grant Review Committee Memberships

  • Alzheimer's Association
  • Environmental Health Research
  • Italian Ministry of Health
  • National Institutes of Health
  • John Douglas French Alzheimer's Foundation
  • U.S. Civilian Research and Development Foundation (CRDF)

Selected Journal Publications

Tanifum EA, Ghaghada K, Vollert C, Head E, Eriksen JL, Annapragada A. A Novel Liposomal Nanoparticle for the Imaging of Amyloid Plaque by Magnetic Resonance Imaging. Alzheimers Dis. 2016;52(2):731-45. doi: 10.3233/JAD-151124.PMID: 27031484

Klionsky DJ, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016;12(1):1-222. doi: 10.1080/15548627.2015.1100356. Erratum in: Autophagy. 2016;12(2):443. Selliez, Iban [corrected to Seiliez, Iban]. PMID: 26799652

Manchandani P, Zhou J, Ledesma KR, Truong LD, Chow DS, Eriksen JL, Tam VH. Characterization of Polymyxin B Biodistribution and Disposition in an Animal Model. Antimicrob Agents Chemother. 2015 Dec 7;60(2):1029-34. doi: 10.1128/AAC.02445-15. PMID: 26643340

Vollert CT, Moree WJ, Gregory S, Bark SJ, Eriksen JL. Formaldehyde scavengers function as novel antigen retrieval agents. Sci Rep. 2015 Nov 27;5:17322. doi: 10.1038/srep17322. PMID: 26612041

Vollert, C.T; Eriksen, J.L. Microglia in the Alzheimer's brain: a help or a hindrance? AIMS Neuroscience. 2014 Dec 9; 1(3): 210-224. doi:10.3934/Neuroscience.2014.3.210#sthash.FJMK89dc.dpuf

Ohia-Nwoko O; Montazari S; Lau YS; Eriksen J.L. Long-term treadmill exercise attenuates tau pathology in P301S tau transgenic mice. Mol Neurodegener. 2014 Nov 28;9(1):54. PMID: 25432085.

Dao, A.T; Zagaar, M.A.; Salim, S.; Eriksen, J.L.; Alkadhi, K.A., Regular exercise prevents non-cognitive disturbances in a rat model of Alzheimer’s disease, International Journal of of Neuropsychopharmacology 2013, 2014 Apr;17(4):593-602. PMID: 24229510.

Vollert, C.; Ohia, O.; Akasaka, H.; Berridge, C.; Ruan, K-H.; Eriksen, J.L., Prostacyclin synthase-overexpression in mice impacts memory and anxiety-like behavior. Behavioural Brain Research 2013 Oct 16. pii: S0166-4328(13)00620-7. doi: 10.1016/j.bbr.2013.10.012. PMID: 24140503.

Hoshino, A.; Helwig, M.; Rezaei, S.; Berridge, C.; Eriksen, J.L.; Lindberg, I., A Novel Function for proSAAS as an amyloid anti-aggregant in Alzheimer’s disease. J Neurochem 2013, Sep 17. doi: 10.1111/jnc.12454. PMID: 24102330.

Vollert, C.; Forkuo, G.; Bond, R.A.; Eriksen, J.L., Chronic treatment with DCPCX, an adenosine A1 antagonist, worsens long-term memory. Neurosci Letters 2013. Aug 26;548:296-300. doi: 10.1016/j.neulet.2013.05.052. Epub 2013 Jun 6. PMID: 23748072.

Thanawala, V.J.; Forkuo, G.S.; Al-Sawalha, N.; Azzegagh, Z.; Nguyen, L.P.; Eriksen, J.L.; Tuvim, M.J.; Lowder, T.W.; Dickey, B.F.; Knoll, B.J.; Walker, J.K.; Bond, R.A., Beta2-adrenoceptor agonists are required for development of the asthma phenotype in a murine model. Am J Respir Cell Mol Biol. 2013 Feb;48(2):220-9. doi: 10.1165/rcmb.2012-0364OC. Epub 2012 Nov 29. PMID: 23204390

Hazra, A.; Gu, F.; Aulakh, A.; Berridge, C.; ‡Eriksen, J.L.; ‡Ziburkus, J., Inhibitory neuron and hippocampal circuit dysfunction in an aged mouse model of Alzheimer's disease. PLoS One 2013, May 17;8(5):e64318. doi: 10.1371/journal.pone.0064318. Print 2013. PMID: 23691195. ‡Corresponding authors.

Helwig, M.; Hoshino, A.; Berridge, C.; Lee, S.N.; Lorenzen, N.; Otzen, D.E.; Eriksen, J.L.; Lindberg, I., The neuroendocrine protein 7B2 suppresses the aggregation of neurodegenerative disease-related proteins. J Biol Chem 2013, 288 (2), 1114-24. PMID: 23172224.

Dao, A.T.; Zagaar, M.A.; Levine, A.T.; Salim, S.; Eriksen, J.L.; Alkadhi, K.A., Treadmill exercise prevents learning and memory impairment in Alzheimer's disease-like pathology. Curr Alzheimer Res 2013, 10 (5), 507-15. PMID: 23627709.

Kim J., Eriksen J.L., Therapeutic targets in neurodegenerative disease. Current Enzyme Inhibition 2013, 9(1), 1-2.

Eriksen J.L., Therapeutic targets in the ubiquitin-proteasome system for Alzheimer's disease. Current Enzyme Inhibition 2013, 9(1), 46-54.

Tanifum, E.A.; Dasgupta, I.; Srivastava, M.; Bhavane, R.C.; Sun, L.; Berridge, J.; Pourgarzham, H.; Kamath, R.; Espinosa, G.; Cook, S.C.; ‡Eriksen, J.L. ; ‡Annapragada, A., Intravenous delivery of targeted liposomes to amyloid-beta pathology in APP/PSEN1 transgenic mice. PLoS One 2012;7(10):e48515. doi: 10.1371/journal.pone.0048515. Epub 2012 Oct 31. PMID: 23119043. ‡Corresponding authors

Alkadhi, K.; Eriksen, J., The complex and multifactorial nature of Alzheimer's disease. Curr Neuropharmacol 2011, 9 (4), 586. doi: 10.2174/157015911798376235. PMID: 22654718

Sun, L. and Eriksen, JL. Recent Insights into the Involvement of Progranulin in Frontotemporal Dementia. Current Neuropharmacology. 2011 Dec;9(4):632-42.

Eriksen JL. The enigmatic roles of microglial versus neuronal progranulin in neurological disease. Acta Neuropathol. 2010 Jan;119(1):107-9.

C. Cook, J. Gass, J. Dunmore, J. Tong, J. Taylor, J. Eriksen, E. McGown, J. Lewis, J. Johnston, L. Petrucelli. Aging is not associated with proteasome dysfunction in UPS reporter mice. PLoS One. 2009 Jun 11;4(6):e5888.

R. Rademakers, J.L. Eriksen, M.C. Baker, T. Robinson, Z. Ahmed, S.J. Lincoln, N.J. Rutherford, R.J. Crook, N. Finch, D.A. Stroh, K.A. Josephs, B.F. Boeve, D.S. Knopman, R.C. Petersen, J.E. Parisi, R.J. Caselli, Z.K. Wszolek , R.J. Uitti, H. Feldman, M.L. Hutton , I.R. Mackenzie, N.R. Graff-Radford and D.W. Dickson. Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. Human Molecular Genetics. 2008 Dec 1;17(23):3631-42. Doi: 10.1093/hmg/ddn257

T.L. Kukar, T.B. Ladd, M.A. Bann, P.C. Fraering, R. Narlawar, A. Welzel, R.W. Price, J.L. Eriksen, K. Jansen-West, B.A. Cottrell, C. Verbeeck, B. Schmidt, D. Walsh, M.S. Wolfe, A. Fauq, E.H. Koo, T.E. Golde. Substrate Targeting by γ-Secretase Modulators. 2008 Jun 12. Nature. 453 (7197):925-9.

J.L. Eriksen and I.R. Mackenzie. Progranulin: normal function and role in neurodegeneration. J. Neurochem. 2008 Jan;104(2):287-97.

S. Weggen*, M. Rogers, J.L. Eriksen*,**. NSAIDs: small molecules for prevention of Alzheimer’s disease or precursors for future drug development? Trends in Pharmacological Sciences. 2007. *Corresponding author; **Senior author. 2007 Oct. 2007 Oct;28(10):536-43.

T. Kukar, S. Prescott, J.L. Eriksen, V. Holloway, M.P. Murphy, E.H. Koo, T.E. Golde, M.M. Nicolle. Chronic administration of r-flurbiprofen attentuates cognitive learning impairments in transgenic APP mice. 2007. Biomed Central. 2007 Jul 24;8:54.

J.L. Eriksen and C. Janus. Plaques, Tangles and memory loss in mouse models of neurodegeneration. Behavior Genetics. 2007 Jan;37(1):79-100.

M. Baker, I.R. MacKenzie, S.M. Pickering-Brown, J. Gass, R. Rademakers, C. Lindholm, J. Snowden, J. Adamson, A.D. Sadovnick, S. Rollinson, A. Cannon, E. Dwosh, D. Neary, S. Melquist, A. Richardson, D. Dickson, Z. Berger, J. Eriksen, T. Robinson, C. Zehr, C.A. Dickey, R. Crook, E. McGowan, D. Mahn, B. Boeve, H. Feldman and M. Hutton. Mutations in Progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature. 2006 Aug 24;442(7105):916-9.

Z. Amtul, N. Kausar, C. Follmer, R.F. Rozmahel, Atta-Ur-Rahman, S.A. Kazmi, M.S. Shekhani, J.L. Eriksen, K.M. Khana and M.I. Choudharya. Cysteine based novel noncompetitive inhibitors of urease(s)—Distinctive inhibition susceptibility of microbial and plant ureases. Bioorganic & Medicinal Chemistry. 2006. 2006 Oct 1;14(19):6737-44.

S. Le Corre, H.W. Klafki, N. Plesnila, G. Hübinger, H. Sahagún, B. Monse, P. Seneci, J. Lewis, J. Eriksen, C. Zehr, M. Yue, E. McGowan, D.W. Dickson, M. Hutton, H.M. Roder. A novel inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proceedings of the National Academy of Sciences. 2006 June 20. 103 (5). 9673-9678,

E. McGowan, J. Eriksen, M. Hutton. A decade of modeling AD in transgenic mice. Trends in Genetics. 2006 May. 22 (5). 281-289.

E. McGowan, F. Pickford, L. Onstead, J. Eriksen, C. Yu, J. Kim, L. Skipper, M.P. Murphy, P. Das, K. Jansen, M. De Lucia, W-L Lin, G. Dolios, R. Wang, D.W. Dickson, M. Hutton, J. Hardy and T. Golde. Aβ42 is essential for Parenchymal and Vascular Amyloid Deposition in Mice. Neuron. 2005 July 21. 47. 191-199.

T. Kukar*, M.P. Murphy*, J.L. Eriksen*, SA Sagi*, S. Weggen, T.E. Smith, T. Ladd, M.A. Khan, J. Beard, M. Dodson, S. Merit, V.V. Ozols, P.Z. Anastasiadis, P. Das, A. Fauq, E.H. Koo and T.E. Golde. Diverse compounds mimic Alzheimer’s disease-causing mutations by augmenting Aβ42 production. Nature Medicine. 2005 May;11(5):545-50.  *co-first author

J.L. Eriksen, S. Przedborski S, L. Petrucelli. Gene Dosage and Pathogenesis of Parkinson’s Disease. Trends in Molecular Medicine. 2005 March 5.

C.A. Dickey, J. Eriksen, A. Kamal, F. Burrows, M. Hutton, C.B. Eckman, L. Petrucelli. Development of a High Throughput Drug Screening Assay for the Detection of Decreases in Tau Expression Elicited by Novel HSP90 Inhibitors. Current Alzheimer’s Research. 2005 April 2. 231-8.

J.L. Eriksen, Z. Wszolek, L. Petrucelli. Molecular Pathogenesis of Parkinson’s Disease. Archives of Neurology. 2005 Mar. 353-7.

J.L. Eriksen and L. Petrucelli. Parkinson’s Disease – Molecular Mechanisms of Disease. Drug Discovery Today: Disease Mechanisms, 2005. 1 (4). 399-405.

Book Chapters

J. Eriksen, M.P. Murphy, E. Head. “Chapter 7. Pharmacological models for preclinical testing: from mouse to dog to non-human primates.” In BACE: Lead Target for orchestrated therapy of Alzheimer’s disease. Editor John Varghese, Ph.D. John Wiley and Sons. 2009.

S. Weggen1, E. Czirr, S. Leuchtenberger, and J. Eriksen1,2. Non-steroidal anti-inflammatory drugs (NSAIDs) and derived AΒ42-lowering molecules for treatment and prevention of Alzheimer’s disease (AD). Pharmacological Mechanisms in Alzheimer's Therapeutics. A. Claudio Cuello, ed. Springer Verlag. 2008. 1Corresponding author; 2Senior author.

J.L. Eriksen, C. Zehr, J. Lewis. Biologic Models of Neurodegenerative Disorders. Handbook of Clinical Neurology, 3rd Series. 2008. 89. 173-188. PMID: 18631742.

Presentations & Abstracts

Oral Presentations at Regional, National and International Meetings

Eric Tanifum, PhD, Ananth Annapragada, PhD, Ketan Ghaghada, PhD, Zbigniew Starosolski, PhD, Jason Eriksen, PhD, Craig Vollert. Novel Nanoparticle Enables T1­MR Imaging of Amyloid Plaques in Two Mouse Models of Amyloid Deposition. Alzheimer’s Association International Conference, Washington DC, July 18-23, 2015.

Eriksen, J.L. Bazelides Research Symposium, Panel Member, Rice University. Alzheimer’s Association, Houston and Southeast Texas Chapter. Bioscience Research Collaborative, Houston, Texas. September 12, 2013. Invited speaker.

Eriksen, J.L., Imaging Alzheimer’s Disease. Bazelides Research Symposium, Houston, Texas, October 17, 2011. Invited speaker.

Eriksen, J.L., Nanoparticle Based Molecular Imaging of Cerebral Amyloid Angiopathy, A Major Risk Factor for Stroke. Alliance for Nanohealth, February 23, 2010. The University of Texas Health Science Center, 1825 Pressler Street, Houston, Texas 77030. Invited speaker.

Eriksen, J.L., Panel member, Town Hall Meeting, World Alzheimer’s Day, Rice University, Herring Hall. September 21, 2009. Invited speaker.

Eriksen, J.L., The Role of Progranulin in Neurodegeneration. Meeting of the German Society of Neuropathology and Neuroanatomy. September 16-19, 2009. Düsseldorf, Germany. Invited Keynote speaker.

Eriksen, J.L., Progranulin and Alzheimer’s Disease. June 17, 2009. Bazelides Research Symposium. UT School of Public Health, Houston, TX. Invited speaker.

Eriksen, J.L., Let’s Talk Trash! Bazelides Research Update. Kaplan Theatre-Jewish Community Center. Houston, Texas. June 16, 2009. Invited speaker.

Hutton, M.; Melquist, S.; Baker, M.; Zehr, C.; McGowan, E.; Dickson, D.; Eriksen, J.L.; Ashe, K.; Stephan, D.; Lewis, J., The Tauopathies: From Genetics to Animal Models. The 10th Annual Conference on Alzheimer’s Disease and Related Disorders, 2006, Madrid, Spain.

Lewis, J.; Zehr, C.; Andorfer, C.; Eriksen, J.L.; Knight, J.; Yue, M.; Robinson, T.; Berger, Z.; Hanna, A.; Dickson, D.W.; Janus, C.; McGowan, E.; Hutton, M. Methods of Cell Death and Recovery in the rTg4510 and IP301L Inducible Mouse Models of Tauopathy. The 10th Annual Conference on Alzheimer’s Disease and Related Disorders, 2006, Madrid, Spain.

Hutton, M.; Lewis, J.; Zehr C.; McGowan, E.; Dickson, D.W.; Eriksen, J.L.; Petrucelli, L.; Hyman, B.; Hsiao-Ashe, K., Neurodegeneration and Functional Deficits in Mouse Models of Tauopathy. 7th Annual Conference AD/PD 2005. Sorrento, Italy.

Petrucelli, L.; Eriksen, J.L.; Taylor, J. P.; Kehoe, K.; McGowan, E.; Kopito, R.R.; Golde, T. E.; Dickson, D. W.; Hutton, M., Monitoring of Proteasome Activity in Neurodegenerative Disease using a Transgenic Mouse Model. Society for Neuroscience, 2004, San Diego, CA.

Eriksen, J.L.; McLendon, C.; Monnier, T.; Weggen, S.; Sagi, S.A.; Ozols, V.V.; Fauq, A.; Khan, M.; Howard, V.; Koo, E.H.; Golde, T.E., NSAIDs Decrease Aβ42 Production by Direct Modulation of Gamma Secretase Activity. Society for Neuroscience, 2002, Orlando, FL.

Institutional Presentations

Eriksen, J.L., Fit Body Fit Mind: The Surprising Science of Exercise and Alzheimer’s Disease. Blaffer Gallery Innovation Series, University of Houston. January 28, 2015. Invited Speaker.

Eriksen, J.L., New Roles for the Old: Prostacyclin in Brain Health and Behavior. Huffington Center on Aging, Baylor College of Medicine. December 6, 2013. Invited speaker.

Eriksen, J.L., The Peak and Treat Approach to Alzheimer Disease. The University of Texas Medical Branch at Galveston (UTMB). May 20, 2013. Invited speaker.

Eriksen, J.L., New Roles for the Old: Prostacyclin in Brain Health and Behavior. University of Houston. Biology of Behavior Institute Annual Retreat, Houston Arboretum, Houston, Texas, June 1, 2013.

Eriksen, J.L., Alzheimer’s Disease: Cracks Within the Enchanted Loom. University of Houston. Biology of Behavior Institute Brown Bag Seminar Series, Houston, Texas, November 9, 2012.

Eriksen, J.L.; Annapragada, A., Peek and Treat: Theranostic Particles for Alzheimer Disease. University of Texas Health Science Center, Department of Pathology and Laboratory Medicine, Houston, Texas, January 14, 2011. Invited speaker.

Eriksen, J.L., Adventures in Biomedical Research, Undergraduate Association of the American Chemical Society, University of Houston, Houston, Texas, October 30, 2009. Invited speaker.

Eriksen, J.L., Selected NSAIDs Lower Aβ42 Production. Centocor Corporation. Feb 7, 2003. Malvern, PA. Invited speaker.

Poster Presentations

Eriksen, J.L.; Vollert, C.; Schmitt, M.; Ohia, O.; Montazari, S. Modulatory effects of prostacyclin in the mouse model of Alzheimer’s disease. Society for Neuroscience. November 15-19, 2014. Washington, D.C.

Vollert, C.; Ngo, K.; Pourzargham, H.; Eriksen, J.L. The effect of progranulin loss on an Alzheimer’s mouse model. Society for Neuroscience. November 15-19, 2014. Washington, D.C.

Ohia, O.; Montazari, S.; Vollert, C.; Eriksen, J.L. Preventative effects of chronic treadmill exercise on cognitive and non-cognitive behaviors in P301S tau transgenic mice. Society for Neuroscience. November 15-19, 2014. Washington, D.C.

Manchandani, P.; Eriksen, J.L.; Tam, V.H.; Distribution of Polymyxin B within the Kidney. Interscience Conference on Antimicrobial Agents and Chemotherapy, September 5-9, 2014. Washington, D.C.

Eriksen, J.L.; Vollert, C.; Forkuo, G.S.; Bond, R.A. Chronic treatment with an adenosine a1 antagonist worsens long-term memory. Society for Neuroscience. November 9-13, 2013. San Diego, California.

Ohia, O.; Vollert, C.; Akasaka, H.; Berridge, C; Ruan, K-H.; Eriksen, J.L., Elevated prostacyclin biosynthesis in mice impacts memory and anxiety-like behavior. Society for Neuroscience. November 9-13, 2013. San Diego, California.

Vollert, C.; Gregory, S.; Ngo, K.; Pourgarzham, H.; Eriksen, J.L., Behavior and neuropathology in a progranulin haploinsufficient mouse model. Society for Neuroscience. November 9-13, 2013. San Diego, California.

Tanifum, E.; Annapragada, A.; Dasgupta, I.; Cook, S.; Eriksen, J.L., Intravenous Delivery of Targeted Liposomes to Cerebral Amyloid Deposits in APP/PSEN1 Transgenic Mice. Radiological Society of North America. November 25-30, 2012. McCormick Place, Chicago.

Ohia, O.; Pourgarzham, H.; Eriksen, J.L., Effects of chronic exercise on neurodegeneration and neuroinflammation in P301S tau transgenic mice. Society for Neuroscience. October 13-17, 2012. New Orleans, Louisana,

Eriksen, J.L.; Hazra A, Gu F, Aulakh A, Berridge C, Žibukus J; Inhibitory neuron and hippocampal circuit dysfunctions in a model of alzheimer’s disease. Society for Neuroscience, New Orleans, Louisana, October 13-17, 2012.

Vollert, C.; Ngo, K.C.; Pourgarzham, H.; Gerton, G.L., Eriksen, J.L., Behavioral effects of progranulin loss on a transgenic mouse model through aging. Society for Neuroscience, New Orleans, Louisiana, October 13-17, 2012.

Hoshino, A.; Helwig, M; Berridge, C.; Eriksen, J.L.; Lindberg, I., The neuroendocrine protein proSAAS prevents neurodegenerative disease-related protein aggregation. Society for Neuroscience, New Orleans, Louisiana, October 13-17, 2012.

Ohia O, Pourzargham H, Kurz M.J., Lau Y-S, Eriksen, J. Effect of long-term exercise in a mouse model of Alzheimer’s disease. November 12-16, 2011. Society for Neuroscience, Washington, DC.

Hoshino, M. Helwig, C. Berridge, J. Eriksen, and I. Lindberg. Structure-function analysis of proSAAS as an Aβ1-42 anti-aggregant. Alzheimer’s Drug Discovery Foundation, September 26-27, 2011, Jersey City, New Jersey.

Tanifum E, Dasgupta I, Sun L, Ghaghada K, Annapragada A, Eriksen J. Development of Amyloid-Beta targeting nanoparticles for imaging and therapy. Society for Neuroscience, November 13-17, 2010, San Diego, California.

Tanifum E, Dasgupta I, Sun L, Ghaghada K, Annapragada A, Eriksen J. Development of Amyloid-Beta targeting nanoparticles for imaging and therapy. Biomedical Engineering Society Annual Meeting, October 6-9, 2010, Austin Texas.

Tanifum E, Dasgupta I, Sun L, Ghaghada K, Annapragada A, Eriksen J. Development of Amyloid-Beta targeting nanoparticles for imaging and therapy. Alzheimer’s Association Research Symposium, August 4, 2010, Houston, Texas.

E. Tanifum, I. Dasgupta, L. Sun, A. Annapragada, J. Eriksen. Nanoparticle Based Molecular Imaging of Cerebraamyloid Angiopathy, A Major Risk Factor for Stroke, Alliance for Nanohealth, February 23, 2010. The University of Texas Health Science Center at Houston.

J. Ness, M.J. Riemenschneider, S. Baches, J.L. Eriksen, C.U. Pietrzik, G. Reifenberger, S. Weggen. Progranulin (GRN), a protein mutated in frontotemporal dementia with ubiquitinpositive inclusions (FTLD-U), is abundantly expressed in human gliomas Authors: ICAD (2009).

G. E. Kisby, A. Olivas, T. Robinson, J. Eriksen, *P. S. Spencer; The cycad genotoxicant methylazoxymethanol (MAM) disrupts tau metabolism and increases tau phosphorylation during early brain development. Society for Neuroscience, 2008, Washington, D.C.

J.L. Eriksen, C. Zehr, C. Andorfer, M. Yue, J.Knight , T. Robinson, H. Melrose, E. McGowan, D.W. Dickson, M. Hutton, J. Lewis. Progranulin expression is enhanced with age and with the development of tauopathy in mice. Society for Neuroscience, 2007, San Diego, CA.

J.L. Eriksen, Z. Ahmed, W. Lin, A. Innes, T. Robinson, A. Nyborg, C. Zehr, E. McGowan, D.Dickson, M. Hutton. Light and electon Light and electron microscopic immunoreactivity of progranulin in Alzheimer’s Disease and mouse models of AD. Society for Neuroscience, 2007, San Diego, CA.

C. Zehr, Z. He, J.L. Eriksen, M. Yue, J.Knight , T. Robinson, H. Melrose, E. McGowan, D.W. Dickson, M. Hutton, J. Lewis. Deficits in axonal transport and their role in cell death and recovery in the rTg4510 tau mouse model. Society for Neuroscience, 2007, San Diego, CA.

J.L. Eriksen, C. Zehr, Z. Berger, T. Robinson, D. W. Dickson, J. Lewis, M. Hutton. Tau clearance through protein degradation pathways. Society for Neuroscience, 2006, Atlanta, GA.

R. Rademakers, M. Baker, I.R. Mackenzie, S.M. Pickering-Brown, J. Gass, C. Lindholm, J. Snowden, J. Adamson, A.D. Sadovnick, S. Rollinson, A. Cannon, E. Dwosh, D. Neary, S. Melquist, A. Richardson, D. Dickson, Z. Berger, J. Eriksen, T. Robinson, C. Zehr, C.A. Dickey, R. Crook, E. McGowan, D. Mann, B. Boeve, H. Feldman and M. Hutton. Mutations in Progranulin Cause Tau-Negative FTD. The 10th Annual Conference on Alzheimer’s Disease and Related Disorders, 2006, Madrid, Spain.

C. Zehr, W-L. Lin, A. Nylander, T. Robinson, J.L. Eriksen, D.W. Dickson, M. Hutton, J. Lewis. Apoptosis of Oligodendrocytes in an Inducible Model of Tauopathy. The 10th Annual Conference on Alzheimer’s Disease and Related Disorders, 2006, Madrid, Spain.

J.L. Eriksen, C. Zehr, Z. Berger, T. Robinson, J. Lewis, M. Hutton. Tau Clearance through Protein Degradation Pathways. Molecular Chaperones and the Heat Shock Response Meeting, 2006, Cold Spring Harbor, NY.